GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer
Metrics: PDF 1701 views | HTML 1926 views | ?
Jie Ma1,*, Shao-Liang Zhu2,*, Yang Liu3,*, Xiang-Yang Huang1 and Dan-Ke Su1
1Department of Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
2Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
3Department of Radiotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China
*These authors contributed equally to this work
Dan-Ke Su, email: [email protected]
Keywords: GSTP1, breast cancer, treatment outcome, toxicities, meta-analysis
Received: October 07, 2016 Accepted: May 23, 2017 Published: June 16, 2017
This study aimed to investigate the association of the GSTP1 gene polymorphism with the outcomes and toxicities of treatments in breast cancer. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the association of GSTP1 polymorphism with tumour response and toxicities, and the hazard ratios (HRs) and 95% CIs were calculated for the association between GSTP1 polymorphism and overall survival (OS). The statistical analysis showed that the GSTP1 polymorphism was not associated with tumour response or OS. A significant increase in the incidence of toxicities was observed (GA vs. AA OR = 1.45, 95% CI = 1.04–2.01, P = 0.028; GG vs. AA OR = 1.47, 95% CI = 1.03–2.10, P = 0.036; recessive model OR = 1.54, 95% CI = 1.13–2.09, P = 0.006; and allele model OR = 1.35, 95% CI = 1.07–1.71, P = 0.011), especially in the chemotherapy ± surgery group (GA vs. AA OR = 1.64, 95% CI = 1.05–2.56, P = 0.030; recessive model OR = 1.72, 95% CI = 1.17–2.54, P = 0.006; and allele model OR = 1.57, 95% CI = 1.11–2.21, P = 0.010). Our results indicate that the GSTP1 polymorphism may be associated with increased toxicity, especially in patients treated with chemotherapy ± surgery.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.